BNTX — BioNTech SE

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates BNTX Bearish with a Setup Score of 26, net conviction 30, actionability 22. How the Setup Score works →

Total Setup Score26
Directional BiasBearish
Net Conviction30
Actionability22 (in range)

Key signals behind this score

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirt… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$80.96
Market Cap$20.18B
Float106.0M
Shares Outstanding247.9M
P/E (Forward)7.04
Price/Sales (TTM)8.34
vs. Analyst Target+38.7% to analyst PT
Profit Margin-60.87%
Operating Margin (TTM)-55.45%
Revenue (TTM)$2.42B
Earnings Growth (YoY)-43.20%
Dividend RateNone
Analyst Target Price$112.27 (21 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $482M $15.2M $423M -$105M
2021 $18.98B $10.29B $16.07B $15.00B
2022 $17.31B $9.43B $14.32B $13.10B
2023 $3.82B $930M $3.22B $1.38B
2024 $2.75B -$665M $2.21B -$367M
2025 $2.76B -$1.09B $2.14B -$628M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Dec 2025 $899M -$302M
Mar 2026 $120M -$541M
Jun 2026 $106M -$821M
Sep 2026 $1.29B $185M

Ownership & Float

Insider Ownership57.9%
Institutional Ownership21.2%
Short Float2.1%
% of All Funds Holding3.42%
Number of Funds Holding301

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$90.65Near-term / short-term trend
Weekly40-Week SMA$94.65Medium-term trend
Weekly80-Week SMA$99.37Cyclical trend (business cycle)
Weekly200-Week SMA$103.27Secular trend (multi-year)
Monthly10-Month SMA$95.12Near-term monthly trend
Monthly20-Month SMA$98.99Medium-term monthly trend
Monthly40-Month SMA$100.53Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$97.00 resistance 1.09x 0 months ago
$108.00 resistance 1.79x 7 months ago

Historical Earnings Reactions (29 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.16% -0.29% 44.83% 4.81% -7.78%
1 Day -0.39% 0.84% 55.17% 8.28% -9.38%
1 Week -0.02% 0.88% 55.17% 20.16% -23.03%
2 Weeks 2.39% -0.80% 48.28% 34.74% -33.58%
1 Month 7.95% 2.80% 60.71% 100.02% -21.92%

Next earnings: January 22, 2027 (60 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan1.4%42.9%7
Feb-3.8%14.3%7
Mar5.8%57.1%7
Apr7.7%42.9%7
May2.9%57.1%7
Jun3.8%57.1%7
Jul12.4%85.7%7
Aug-2.7%57.1%7
Sep1.3%28.6%7
Oct0.5%57.1%7
Nov19.3%85.7%7
Dec-3.3%28.6%7

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.74% 54.0% 335
Tuesday -0.10% 48.0% 369
Wednesday 0.19% 46.6% 365
Thursday -0.09% 44.1% 358
Friday 0.33% 53.2% 357

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 21.2%

Insider Transactions — Smart Summary

Total insider ownership: 57.9%

Founder-led management: Ugur Sahin (Chief Executive Officer & Chair of the Management Board), Özlem Türeci (Chief Medical Officer & Member of Management Board)

12-Month Insider Activity Summary

Total Filings15
Net Value-$89.8M
Net Shares Change-908,209
% of Float-0.9%
C-Suite Filings15
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Sahin Ugur Chief Executive Officer -$64.7M 9 N/A
Poetting Sierk Chief Operating Officer -$5.5M 1 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-09-08 Sahin Ugur Chief Executive Officer -$7.9M Transaction at $103.12, now -21.5%
2026-04-23 Poetting Sierk Chief Operating Officer -$5.5M Transaction at $110.56, now -26.8%
2026-10-09 Sahin Ugur Chief Executive Officer -$5.9M Transaction at $94.07, now -13.9%
2026-10-06 Sahin Ugur Chief Executive Officer -$9.0M Transaction at $97.14, now -16.7%
2026-09-30 Sahin Ugur Chief Executive Officer -$6.5M Transaction at $98.19, now -17.5%
2026-09-28 Sahin Ugur Chief Executive Officer -$6.0M Transaction at $98.57, now -17.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for BioNTech SE (BNTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for BNTX on Trend Edge →